Select a community
All Communities
Home > Community Treatment Reports > Natalizumab Treatment Report
What is Natalizumab?

Natalizumab is a monoclonal antibody given by infusion and used in the treatment of MS and Crohn's disease. It has been shown to slow progression and reduce relapses in MS. It is currently sold under the brand name Tysabri.

Side Effects

Side effects as an overall problem

Severe
13 6%
Moderate
23 11%
Mild
56 28%
None
109 54%

Most commonly reported side effects

tiredness
48 24%
Headaches
36 18%
fear of PML
24 12%
Head pain
14 7%
quick changes of mood
13 6%
Stomach pain
13 6%
  • Mild
  • Moderate
  • Severe

Dosages

Top 10 dosages based on patients currently taking Natalizumab. See all 21 dosages ►

  300mg/15mL as needed 300mg as needed monthly 1 g monthly 1 mg monthly 1 monthly 4 mg monthly 5 mg monthly 20 mg monthly 25 mg monthly 30 mg monthly 50 mg monthly 100 mg monthly 200 mg monthly 200 mg every 4 weeks 300 mg/15 mL monthly 300 mg monthly 300 mg/15 mL every 4 weeks 2 x 300 mg/15 mL every 4 weeks 1000 mg monthly 300 mg/15 mL daily
  3 Number of Patients: 3 1 Number of Patients: 1 158 Number of Patients: 158 1 Number of Patients: 1 2 Number of Patients: 2 4 Number of Patients: 4 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 4 Number of Patients: 4 1 Number of Patients: 1 247 Number of Patients: 247 42 Number of Patients: 42 189 Number of Patients: 189 1 Number of Patients: 1 1 Number of Patients: 1 14 Number of Patients: 14  

Stop Reasons

Why Patients Stopped Taking Natalizumab (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other
51 34% Other: 34%
Doctor's advice
46 30% Doctor's advice: 30%
Side effects too severe
45 30% Side effects too severe: 30%
Did not seem to work
42 28% Did not seem to work: 28%
Expense
10 7% Expense: 7%
Personal research
3 2% Personal research: 2%
Course of treatment ended
3 2% Course of treatment ended: 2%
Not indicated
3 2% Not indicated: 2%

See all 146 patients who’ve stopped taking Natalizumab

Duration See details about how long patients take this treatment ▼

Currently Taking Natalizumab

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
6
30
44
73
113
94

Stopped Taking Natalizumab

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
15
27
26
40
31
6

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
190 95%
Usually
9 4%
Sometimes
1 0%
Never
1 0%

Burden

Difficulty being on treatment

Very
13 6%
Somewhat
17 8%
A little
63 31%
Not at all
108 54%

Cost

Paid out of pocket

$200+
32 16%
$100-199
10 5%
$50-99
12 6%
$25-49
18 9%
< $25
57 28%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 22, 2009.